^
Association details:
| Biomarker: | CLDN18.2 positive |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | ZL-1211 (CLDN18.2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preliminary results of a phase 1/2, first-in-human, open-label, dose escalation study of ZL-1211 (anti-Claudin 18.2 mAb) in patients with unresectable or metastatic solid tumors.
Published date:
05/25/2023
Excerpt:
This is a first-in-human, phase 1/2, multicenter, dose escalation/cohort expansion study of ZL-1211 administered intravenously to adult patients with Claudin 18.2-positive advanced solid tumors….Three patients had tumor regression: 17.1% in a pancreatic cancer patient of the 5 mg/kg cohort; 14.5% in a pancreatic cancer patient and 24.9% in a gastric cancer patient in the 10 mg/kg cohort....ZL-1211 displayed an acceptable safety/tolerability profile to date and demonstrated preliminary antitumor effects.
DOI:
10.1200/JCO.2023.41.16_suppl.2537
Trial ID:
